SkyOak Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

SkyOak Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,537	Closed	-$337K	–	310
2019 Q4	$337K	Buy	+1,537	New	+$311K	0.1%	215

Other funds holding VRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

SkyOak Wealth's VRTX Position: Q1 2020 in Review

SkyOak Wealth sold out of Vertex Pharmaceuticals (VRTX) in Q1 2020, closing a stake of 1,537 shares — an estimated $337K sold.

SkyOak Wealth first reported a position in VRTX in Q4 2019 and held it in 1 quarter. The position peaked at $337K in Q4 2019. 855 funds tracked by Wall St. Rank hold VRTX as of Q1 2020.

SkyOak Wealth reported no remaining Vertex Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
SkyOak Wealth sold 1,537 Vertex Pharmaceuticals shares in Q1 2020, an estimated $337K.
SkyOak Wealth first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 1 quarter.
SkyOak Wealth's Vertex Pharmaceuticals position peaked at $337K in Q4 2019.
855 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2020.

Based on SkyOak Wealth's 13F filing for Q1 2020, filed 4 May 2020.